Opus Genetics (IRD) Fundamental Analysis: Revenue, Earnings & Valuation

8.36 / 10

Outperform

Fundamental analysis rates IRD as Outperform with an 8.4/10 score. Strengths include high interest coverage, favorable PB‑ROE, strong asset and revenue relative value, robust inventory turnover, and 29% YoY revenue growth. Weak points are zero income‑tax ratio and modest accounts‑receivable turnover.

Analysis Checks(8/10)

Revenue-MV

Value-1.59

Score3/3

Weight27.12%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value29.15

Score2/3

Weight1.44%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-1.54%

1M Return-0.67%

Accounts receivable turnover ratio

Value5.11

Score1/3

Weight-3.84%

1M Return-1.57%

PB-ROE

Value0.74

Score3/3

Weight39.23%

1M Return12.56%

Income tax / Total profit (%)

Value0.00

Score0/3

Weight-3.47%

1M Return-1.54%

Fixed assets turnover ratio

Value62.95

Score3/3

Weight2.03%

1M Return0.79%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-1.72%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-1.69%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight42.43%

1M Return13.09%

Is IRD undervalued or overvalued?

IRD scores 8.36/10 on fundamentals and holds a Discounted valuation at present. Backed by its -242.41% ROE, -349.33% net margin, -6.71 P/E ratio, 21.67 P/B ratio, and 62.79% earnings growth, these metrics solidify its Outperform investment rating.